Company intelligence / Profile preview

HueDx

Philadelphia, Pennsylvania, United Statesinnovationsoftheworld.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company's point-of-care paper microfluidic diagnostic devices can deliver quantitative results from a finger-prick blood sample within about twenty minutes. Initial clinical trials focused on liver function tests at PennMedicine. The technology aims to expand to over sixty test types covering infectious disease, cardiac markers, and basic chemistries. Research collaborations include a liver cancer diagnostic with Mt Sinai.

Therapeutic areas: OncologyEndocrinologyGastroenterologyCardiovascularInfectious Diseases
Modalities: DeviceSoftware platformPaper microfluidic technology
Industry: Protein Biomarker Diagnostics

Partnerships

Research agreement with Mount Sinai Hospital for liver cancer diagnostics development

Beyond the preview

Go deeper on HueDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HueDx.

Explore the full profile